A composition for treating rheumatoid arthritis and a method of preparing and using the same

Abstract

The present application relates to the technical field of rheumatoid arthritis medicine. The present application provides a composition for treating rheumatoid arthritis, and a preparation method and application thereof. The composition comprises the following raw materials in parts by weight: radix aconiti 30-40 parts, radix rehmanniae 30-40 parts, radix codonopsis 15-19 parts, scolopendra 10-12 parts, siler 5-9 parts, ephedra 3-7 parts, schizonepeta 3-7 parts, atractylodes 5-7 parts, mentha 1-3 parts, sellowia 1-3 parts, and saussurea 1-3 parts. The composition of the present application can significantly improve the clinical symptoms of patients with rheumatoid arthritis, and the raw materials are reasonably matched and widely sourced. The use effect is good, and the composition is convenient to popularize and use.

Description

Technical Field

[0001] This invention relates to the field of arthritis drugs, and more particularly to a composition for treating rheumatoid arthritis, its preparation method, and its application. Background Technology

[0002] Rheumatoid arthritis is an autoimmune disease with synovitis as its pathological basis, which may eventually lead to joint deformities. Its etiology is still under investigation, but research suggests that it may be closely related to factors such as autoimmunity, genetics, and microbial infection.

[0003] The clinical manifestations of this disease primarily involve joint involvement. The initial main symptoms are morning stiffness, swelling, and pain in the joints. As the disease progresses, joint deformities may develop, affecting the patient's normal joint function. Some patients may also experience systemic symptoms such as fever, fatigue, and weakness.

[0004] These symptoms significantly impact patients' normal work and daily lives, causing them severe suffering. Therefore, developing new and effective drugs for the treatment of rheumatoid arthritis is of paramount importance. Summary of the Invention

[0005] The purpose of this invention is to provide a composition for treating rheumatoid arthritis, its preparation method and application, which significantly improves the clinical symptoms of patients with rheumatoid arthritis.

[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution:

[0007] This invention provides a composition for treating rheumatoid arthritis, comprising the following raw materials in parts by weight: 30-40 parts of Aconitum carmichaelii, 30-40 parts of Rehmannia glutinosa, 15-19 parts of Codonopsis pilosula, 10-12 parts of Eupolyphaga sinensis, 5-9 parts of Saposhnikovia divaricata, 3-7 parts of Ephedra sinica, 3-7 parts of Schizonepeta tenuifolia, 5-7 parts of Atractylodes macrocephala, 1-3 parts of Mentha haplocalyx, 1-3 parts of Selaginella tamariscina, and 1-3 parts of Aucklandia lappa.

[0008] As a preferred option, the raw materials include the following parts by weight: Aconitum carmichaelii 32-38 parts, Rehmannia glutinosa 32-38 parts, Codonopsis pilosula 16-18 parts, Eupolyphaga sinensis 10.5-11.5 parts, Saposhnikovia divaricata 6-8 parts, Ephedra sinica 4-6 parts, Schizonepeta tenuifolia 4-6 parts, Atractylodes macrocephala 5.5-6.5 parts, Mentha haplocalyx 1.5-2.5 parts, Selaginella tamariscina 1.5-2.5 parts, and Aucklandia lappa 1.5-2.5 parts.

[0009] As a preferred option, the raw materials include the following parts by weight: 35 parts Aconitum carmichaelii, 35 parts Rehmannia glutinosa, 17 parts Codonopsis pilosula, 11 parts Eupolyphaga sinensis, 7 parts Saposhnikovia divaricata, 5 parts Ephedra sinica, 5 parts Schizonepeta tenuifolia, 6 parts Atractylodes macrocephala, 2 parts Mentha haplocalyx, 2 parts Selaginella tamariscina, and 2 parts Aucklandia lappa.

[0010] The present invention also provides the use of the composition in the preparation of products for treating rheumatoid arthritis.

[0011] The present invention also provides a medicament for treating rheumatoid arthritis, the medicament comprising the composition described above.

[0012] Preferably, the dosage form of the drug is an ointment, solution, tincture, powder or paste, and the drug also contains pharmaceutically acceptable excipients.

[0013] The present invention also provides a method for preparing the aforementioned drug, comprising the following steps:

[0014] (1) Weigh out the following ingredients in proportion: Aconitum carmichaelii, Rehmannia glutinosa, Codonopsis pilosula, Eupolyphaga sinensis, Saposhnikovia divaricata, Ephedra sinica, Schizonepeta tenuifolia, Atractylodes macrocephala, Mentha haplocalyx, Selaginella tamariscina and Aucklandia lappa to obtain the raw materials for later use.

[0015] (2) The raw materials are pulverized to obtain a mixture;

[0016] (3) Soak the mixture in water, decoct it, and then separate the decoction and dregs;

[0017] (4) Add water to the dregs and boil them a second time to obtain the second decoction;

[0018] (5) Combine the first decoction and the second decoction and concentrate them to obtain the drug.

[0019] Preferably, the particle size of the mixture obtained after pulverization in step (2) is 40 to 60 mesh.

[0020] Preferably, the mass ratio of the mixture to water in step (3) is 1:7-9, the soaking time is 20-30 min, and the decocting time is 20-25 min;

[0021] The mass ratio of the dregs to water in step (4) is 1:4 to 6, and the second decoction time is 10 to 15 minutes.

[0022] Preferably, the drug obtained after concentration in step (5) has a density of 1.10–1.25 g / cm³. 3 Extract of .

[0023] This invention provides a composition for treating rheumatoid arthritis, its preparation method, and its application. The composition comprises the following raw materials in parts by weight: 30-40 parts of Aconitum carmichaelii, 30-40 parts of Rehmannia glutinosa, 15-19 parts of Codonopsis pilosula, 10-12 parts of Eupolyphaga sinensis, 5-9 parts of Saposhnikovia divaricata, 3-7 parts of Ephedra sinica, 3-7 parts of Schizonepeta tenuifolia, 5-7 parts of Atractylodes macrocephala, 1-3 parts of Mentha haplocalyx, 1-3 parts of Selaginella tamariscina, and 1-3 parts of Aucklandia lappa. The composition of this invention can significantly improve the clinical symptoms of patients with rheumatoid arthritis. The raw materials are rationally combined and widely available. It has good efficacy and is easy to promote and use. Detailed Implementation

[0024] This invention provides a composition for treating rheumatoid arthritis, comprising the following raw materials in parts by weight: 30-40 parts of Aconitum carmichaelii, 30-40 parts of Rehmannia glutinosa, 15-19 parts of Codonopsis pilosula, 10-12 parts of Eupolyphaga sinensis, 5-9 parts of Saposhnikovia divaricata, 3-7 parts of Ephedra sinica, 3-7 parts of Schizonepeta tenuifolia, 5-7 parts of Atractylodes macrocephala, 1-3 parts of Mentha haplocalyx, 1-3 parts of Selaginella tamariscina, and 1-3 parts of Aucklandia lappa.

[0025] In this invention, the composition preferably comprises the following raw materials in parts by weight: 32-38 parts of Aconitum carmichaelii, 32-38 parts of Rehmannia glutinosa, 16-18 parts of Codonopsis pilosula, 10.5-11.5 parts of Eupolyphaga sinensis, 6-8 parts of Saposhnikovia divaricata, 4-6 parts of Ephedra sinica, 4-6 parts of Schizonepeta tenuifolia, 5.5-6.5 parts of Atractylodes macrocephala, 1.5-2.5 parts of Mentha haplocalyx, 1.5-2.5 parts of Selaginella tamariscina, and 1.5-2.5 parts of Aucklandia lappa.

[0026] In this invention, the composition is further preferably composed of the following raw materials in parts by weight: 35 parts of Aconitum carmichaelii, 35 parts of Rehmannia glutinosa, 17 parts of Codonopsis pilosula, 11 parts of Eupolyphaga sinensis, 7 parts of Saposhnikovia divaricata, 5 parts of Ephedra sinica, 5 parts of Schizonepeta tenuifolia, 6 parts of Atractylodes macrocephala, 2 parts of Mentha haplocalyx, 2 parts of Selaginella tamariscina, and 2 parts of Aucklandia lappa.

[0027] Aconitum carmichaelii, the dried tuberous root of Aconitum carmichaelii, a plant in the Ranunculaceae family, is used for wind-cold-dampness arthralgia, joint pain, cold pain in the heart and abdomen, hernia pain, and as an anesthetic and analgesic.

[0028] Rehmannia root has a sweet and bitter taste, is cold in nature and non-toxic, and enters the heart, liver, spleen and lung meridians. It cools the heart fire and relieves vexation and heat, drains damp heat from the spleen, stops nosebleeds from the lung meridian, and removes blood heat from the liver.

[0029] Codonopsis pilosula, the dried root of Codonopsis pilosula, Codonopsis lanceolata, or Codonopsis chuanxiong, all belonging to the Campanulaceae family, is used to replenish qi and blood, quench thirst, strengthen the spleen and lungs, and nourish blood and generate body fluids. It is indicated for spleen and lung qi deficiency, poor appetite and fatigue, cough and wheezing, qi and blood deficiency, sallow complexion, palpitations and shortness of breath, thirst due to fluid depletion, and internal heat and thirst.

[0030] The ground beetle is salty and cold in nature, and enters the liver meridian. It has the effects of breaking up blood stasis, promoting blood circulation, and healing tendons and bones. It is used for traumatic injuries, tendon injuries and fractures, blood stasis and amenorrhea, postpartum abdominal pain due to blood stasis, and abdominal masses.

[0031] Saposhnikovia root is the root of the Apiaceae plant Saposhnikovia divaricata. It is used for external pathogenic factors, urticaria and itching, rheumatic pain, tetanus, and spleen deficiency with dampness.

[0032] Ephedra, which induces sweating and relieves exterior syndromes, is pungent, slightly bitter, and warm in nature. It is used to clear the lungs, relieve asthma, promote diuresis, and reduce swelling.

[0033] Schizonepeta tenuifolia is the dried aerial part of the plant Vitex negundo, belonging to the Lamiaceae family. It is used to relieve exterior syndromes, dispel wind, promote rash eruption, and eliminate sores.

[0034] Atractylodes macrocephala has the effects of tonifying qi and strengthening the spleen, drying dampness and promoting diuresis, stopping sweating, and calming the fetus.

[0035] Peppermint disperses wind-heat, clears the head and eyes, soothes the throat and promotes rash eruption, and soothes the liver and regulates qi.

[0036] Selaginella, the dried whole herb of Selaginella tamariscina or Selaginella materia var. pachyphylla, belonging to the Selaginellaceae family. It has the effect of promoting blood circulation and regulating menstruation. It is used for amenorrhea, dysmenorrhea, abdominal masses, and injuries from falls.

[0037] Costus root, the dried root of the Costus root plant (family Asteraceae), has the effects of regulating qi and relieving pain, strengthening the spleen and aiding digestion.

[0038] The present invention also provides the use of the composition in the preparation of products for treating rheumatoid arthritis.

[0039] The present invention also provides a medicament for treating rheumatoid arthritis, the medicament comprising the composition described above.

[0040] In this invention, the dosage form of the drug is preferably an ointment, solution, tincture, powder or paste, and the drug preferably also contains pharmaceutically acceptable excipients.

[0041] The present invention also provides a method for preparing the aforementioned drug, comprising the following steps:

[0042] (1) Weigh out the following ingredients in proportion: Aconitum carmichaelii, Rehmannia glutinosa, Codonopsis pilosula, Eupolyphaga sinensis, Saposhnikovia divaricata, Ephedra sinica, Schizonepeta tenuifolia, Atractylodes macrocephala, Mentha haplocalyx, Selaginella tamariscina and Aucklandia lappa to obtain the raw materials for later use.

[0043] (2) The raw materials are pulverized to obtain a mixture;

[0044] (3) Soak the mixture in water, decoct it, and then separate the decoction and dregs;

[0045] (4) Add water to the dregs and boil them a second time to obtain the second decoction;

[0046] (5) Combine the first decoction and the second decoction and concentrate them to obtain the drug.

[0047] In this invention, the particle size of the mixture obtained after pulverization in step (2) is preferably 40 to 60 mesh.

[0048] In this invention, the mass ratio of the mixture to water in step (3) is preferably 1:7 to 9, more preferably 1:8, the soaking time is preferably 20 to 30 min, more preferably 22 to 28 min, and even more preferably 25 min, and the decocting time is preferably 20 to 25 min, more preferably 22 to 23 min.

[0049] In this invention, the mass ratio of the dregs to water in step (4) is preferably 1:4 to 6, more preferably 1:5, and the time for the second decoction is preferably 10 to 15 minutes, more preferably 12 to 13 minutes.

[0050] In this invention, the drug obtained after concentration in step (5) is preferably 1.10–1.25 g / cm³. 3 The extract is further preferably having a density of 1.15–1.20 g / cm³. 3 The extract is further preferably having a density of 1.17–1.18 g / cm³. 3 Extract of .

[0051] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0052] Example 1

[0053] A method for preparing a drug for treating rheumatoid arthritis includes the following steps:

[0054] (1) Prepare raw materials according to the following mass ratio: 30 parts Aconitum carmichaelii, 30 parts Rehmannia glutinosa, 19 parts Codonopsis pilosula, 12 parts Eupolyphaga sinensis, 9 parts Saposhnikovia divaricata, 3 parts Ephedra sinica, 7 parts Schizonepeta tenuifolia, 5 parts Atractylodes macrocephala, 1 part Mentha haplocalyx, 1 part Selaginella tamariscina, and 3 parts Aucklandia lappa.

[0055] (2) Grind the raw materials to 60 mesh to obtain a mixture;

[0056] (3) Soak the mixture in 9 times its weight of water for 20 minutes, decoct for 25 minutes, and then separate the decoction and dregs.

[0057] (4) Add 4 times the mass of water to the dregs and boil for 15 minutes for a second time, then separate the second decoction.

[0058] (5) Combine the first and second decoctions and concentrate to obtain 1.25 g / cm³. 3 Extract of .

[0059] Example 2

[0060] A method for preparing a drug for treating rheumatoid arthritis includes the following steps:

[0061] (1) Prepare raw materials according to the following mass ratio: 40 parts Aconitum carmichaelii, 40 parts Rehmannia glutinosa, 15 parts Codonopsis pilosula, 10 parts Eupolyphaga sinensis, 5 parts Saposhnikovia divaricata, 7 parts Ephedra sinica, 3 parts Schizonepeta tenuifolia, 7 parts Atractylodes macrocephala, 3 parts Mentha haplocalyx, 3 parts Selaginella tamariscina, and 1 part Aucklandia lappa.

[0062] (2) Grind the raw materials to 40 mesh to obtain a mixture;

[0063] (3) Soak the mixture in 7 times its weight of water for 30 minutes, decoct for 20 minutes, and then separate the decoction and dregs.

[0064] (4) Add 6 times the mass of water to the dregs and boil for 10 minutes for a second time, then separate the decoction to obtain the second decoction.

[0065] (5) Combine the first and second decoctions and concentrate to obtain 1.10 g / cm³. 3 Extract of .

[0066] Example 3

[0067] A method for preparing a drug for treating rheumatoid arthritis includes the following steps:

[0068] (1) Prepare raw materials according to the following mass ratio: 35 parts Aconitum carmichaelii, 35 parts Rehmannia glutinosa, 17 parts Codonopsis pilosula, 11 parts Eupolyphaga sinensis, 7 parts Saposhnikovia divaricata, 5 parts Ephedra sinica, 5 parts Schizonepeta tenuifolia, 6 parts Atractylodes macrocephala, 2 parts Mentha haplocalyx, 2 parts Selaginella tamariscina, and 2 parts Aucklandia lappa.

[0069] (2) Grind the raw materials to 50 mesh to obtain a mixture;

[0070] (3) Soak the mixture in 8 times its weight of water for 25 minutes, decoct for 23 minutes, and then separate the decoction and dregs.

[0071] (4) Add 5 times the weight of water to the dregs and boil for 13 minutes for a second time, then separate the second decoction.

[0072] (5) Combine the first and second decoctions and concentrate to obtain 1.15 g / cm³. 3 Extract of .

[0073] Test Example 1: Drug Safety Test

[0074] Forty rats, weighing 200±10g, were randomly divided into four groups of 10 rats each, numbered as experimental group 1-3 and control group 1.

[0075] Rats in experimental group 1 were fed the extract prepared in Example 1; rats in experimental group 2 were fed the extract prepared in Example 2; rats in experimental group 3 were fed the extract prepared in Example 3; rats in control group 1 were not fed any additional extract.

[0076] During the experiment, rats in experimental groups 1-3 were fed the extract twice daily, morning and evening, with each dose being 0.08g. The experiment lasted for 14 days, during which time the rats in each group had free access to food and water. The survival status of the rats in each group was checked after the experiment.

[0077] result:

[0078] After the experiment, no rats in experimental groups 1-3 died, and their behavior, activity, and condition were no different from those in control group 1. This indicates that the composition prepared in this application has good safety.

[0079] Experiment Example 2: Animal Experiment

[0080] 1. Experimental animals:

[0081] Another 60 rats, weighing 200±10g, were taken and divided into a model group and a control group 2, with 50 rats in the model group and 10 rats in the control group 2.

[0082] 2. Construction of a rheumatoid arthritis model:

[0083] Bovine type II collagen powder was dissolved in glacial acetic acid to prepare a solution with a concentration of 2 mg / mL. The solution was then mixed with an equal volume of Freund's complete adjuvant and fully emulsified on ice to prepare an emulsion with a final bovine type II collagen concentration of 1 mg / mL.

[0084] After anesthetizing rats, the drug was administered via tail root injection and intradermal injection. The model group received the initial immunization (day 1) with a prepared emulsion at a dose of 0.1 mL / 100 g. The control group received the same dose of physiological saline. A booster immunization was administered at the end of the second week using the same method. On day 7 after the booster immunization, the rats' ankles showed mild swelling and skin redness. On day 19, skin ulcers appeared. On day 35, changes in the paws were measured; the paws of the model group were significantly larger than those of the control group. Erosion of the articular cartilage and subchondral bone was observed in the model group rats. Visually, the model group rats showed dull fur, slight hair loss, weight loss, and inflammatory lesions on the ears and tail. One or more joints were visibly red and swollen, and the animals experienced difficulty moving. The model was successfully established.

[0085] 3. Experimental Grouping:

[0086] Thirty rats with arthritis symptoms and similar body weight were selected from the rat model group and divided into three groups of 10 each, numbered as experimental groups 4 to 6.

[0087] 4. Sample preparation

[0088] The drug prepared in Example 1 was dissolved in 40 times its mass of water to obtain Sample 1. The drug prepared in Example 2 was dissolved in 40 times its mass of water to obtain Sample 2. The drug prepared in Example 3 was dissolved in 40 times its mass of water to obtain Sample 3.

[0089] 5. Treatment Trial

[0090] Rats in experimental group 4 had their joints exhibiting rheumatoid arthritis symptoms soaked in sample 1 twice daily, morning and evening, for 10 minutes each time. Rats in experimental group 5 used sample 2, rats in experimental group 6 used sample 3, and rats in control group 2 used physiological saline, all treated using the same method. Treatment continued for 21 consecutive days. During the experiment, rats in all groups had free access to food and water. After the experiment, the arthritis symptoms of rats in experimental groups 4–6 were compared with those of rats in control group 2.

[0091] Judgment criteria:

[0092] Full recovery: Symptoms such as joint swelling, redness, and ulceration are completely eliminated; paw size is comparable to control group 2; symptoms of articular cartilage and subchondral bone erosion disappear; coat is glossy; weight is restored; inflammation subsides; and movement is free.

[0093] Significant improvement: Symptoms such as joint swelling, redness, and ulceration were reduced; paw size was comparable to or close to that of control group 2; symptoms of articular cartilage and subchondral bone erosion disappeared; fur became glossy; weight difference was not significant; inflammation subsided; and behavior was similar to that of control group 2.

[0094] No significant improvement observed: The symptoms showed no significant improvement compared to before the start of the trial.

[0095] result:

[0096] In experimental group 4, 6 rats recovered completely and 4 showed significant improvement; in experimental group 5, 4 rats recovered completely and 4 showed significant improvement, while 1 showed no significant improvement; in experimental group 6, 8 rats recovered completely and 2 showed significant improvement.

[0097] Example 3: Statistical Analysis of Actual Treatment Effects

[0098] Case 1: Ms. Li, 44 years old. She presented with swollen and burning ankles, experiencing severe pain that made standing difficult. She was diagnosed with rheumatoid arthritis at the Jinshan Branch of Shanghai Sixth People's Hospital. She applied and soaked her joints with the medication prepared according to this invention. After 16 consecutive days of use, her symptoms completely disappeared. She continued use for another 12 days before discontinuing the medication. A follow-up six months later showed no recurrence.

[0099] Case 2: Mr. Xi, male, 51 years old. He presented with migratory pain in both shoulder joints, which worsened in humid and cold weather, and had been present for over three years. He was diagnosed with rheumatoid arthritis at the Jinshan Branch of Shanghai Sixth People's Hospital. He used the medication prepared according to this invention for topical application and joint soaking. After 19 consecutive days of use, his symptoms disappeared. He continued use for another 16 days before discontinuing the medication. A follow-up six months later showed no recurrence.

[0100] Case 3: Ms. Liu, 49 years old. She experienced pain in both elbows and wrists, and numbness in her fingers. Each episode lasted more than 15 days, and the condition worsened in humid weather. She was diagnosed with rheumatoid arthritis at the Jinshan Branch of Shanghai Sixth People's Hospital. She applied and soaked her joints with the medication prepared according to this invention. After 13 days of continuous use, her symptoms disappeared. She continued use for another 15 days before discontinuing the medication. A follow-up six months later showed no recurrence.

[0101] As can be seen from the above embodiments, the present invention provides a composition for treating rheumatoid arthritis, its preparation method, and its application. The composition comprises the following raw materials in parts by weight: 30-40 parts of Aconitum carmichaelii, 30-40 parts of Rehmannia glutinosa, 15-19 parts of Codonopsis pilosula, 10-12 parts of Eupolyphaga sinensis, 5-9 parts of Saposhnikovia divaricata, 3-7 parts of Ephedra sinica, 3-7 parts of Schizonepeta tenuifolia, 5-7 parts of Atractylodes macrocephala, 1-3 parts of Mentha haplocalyx, 1-3 parts of Selaginella tamariscina, and 1-3 parts of Aucklandia lappa. The composition of the present invention can significantly improve the clinical symptoms of patients with rheumatoid arthritis. The raw materials are rationally combined and widely available. It has good efficacy and is easy to promote and use.

[0102] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A composition for treating rheumatoid arthritis, characterized in that, It is composed of the following raw materials in parts by weight: Aconitum carmichaelii 30-40 parts, Rehmannia glutinosa 30-40 parts, Codonopsis pilosula 15-19 parts, Eupolyphaga sinensis 10-12 parts, Saposhnikovia divaricata 5-9 parts, Ephedra sinica 3-7 parts, Schizonepeta tenuifolia 3-7 parts, Atractylodes macrocephala 5-7 parts, Mentha haplocalyx 1-3 parts, Selaginella tamariscina 1-3 parts, and Aucklandia lappa 1-3 parts.

2. The composition according to claim 1, characterized in that, It is composed of the following raw materials in parts by weight: Aconitum carmichaelii 32-38 parts, Rehmannia glutinosa 32-38 parts, Codonopsis pilosula 16-18 parts, Eupolyphaga sinensis 10.5-11.5 parts, Saposhnikovia divaricata 6-8 parts, Ephedra sinica 4-6 parts, Schizonepeta tenuifolia 4-6 parts, Atractylodes macrocephala 5.5-6.5 parts, Mentha haplocalyx 1.5-2.5 parts, Selaginella tamariscina 1.5-2.5 parts, and Aucklandia lappa 1.5-2.5 parts.

3. The composition according to claim 1 or 2, characterized in that, It is composed of the following ingredients in parts by weight: Aconitum carmichaelii 35 parts, Rehmannia glutinosa 35 parts, Codonopsis pilosula 17 parts, Eupolyphaga sinensis 11 parts, Saposhnikovia divaricata 7 parts, Ephedra sinica 5 parts, Schizonepeta tenuifolia 5 parts, Atractylodes macrocephala 6 parts, Mentha haplocalyx 2 parts, Selaginella tamariscina 2 parts, and Aucklandia lappa 2 parts.

4. Use of the composition according to any one of claims 1 to 3 in the preparation of a medicament for treating rheumatoid arthritis.

5. A medicament for treating rheumatoid arthritis, characterized in that, The drug contains the composition according to any one of claims 1 to 3.

6. The drug according to claim 5, characterized in that, The dosage form of the drug is an ointment, solution, tincture, powder or paste, and the drug also contains pharmaceutically acceptable excipients.

7. The method for preparing the drug according to claim 5 or 6, characterized in that, Includes the following steps: (1) Weigh out the following ingredients in proportion: Aconitum carmichaelii, Rehmannia glutinosa, Codonopsis pilosula, Eupolyphaga sinensis, Saposhnikovia divaricata, Ephedra sinica, Schizonepeta tenuifolia, Atractylodes macrocephala, Mentha haplocalyx, Selaginella tamariscina and Aucklandia lappa to obtain the raw materials for later use. (2) The raw materials are pulverized to obtain a mixture; (3) Soak the mixture in water, decoct it, and then separate the decoction and dregs; (4) Add water to the dregs and boil them a second time to obtain the second decoction; (5) Combine the first decoction and the second decoction and concentrate them to obtain the drug.

8. The preparation method according to claim 7, characterized in that, The particle size of the mixture obtained after crushing in step (2) is 40~60 mesh.

9. The preparation method according to claim 8, characterized in that, The mass ratio of the mixture to water in step (3) is 1:7~9, the soaking time is 20~30 min, and the decocting time is 20~25 min; The mass ratio of the dregs to water in step (4) is 1:4~6, and the second decoction time is 10~15min.

10. The preparation method according to any one of claims 7 to 9, characterized in that, The drug obtained after concentration in step (5) has a density of 1.10~1.25 g / cm³. 3 Extract of .